Annals of Surgical Oncology

, Volume 15, Issue 7, pp 2034–2041 | Cite as

A Single-Institution Validation of the AJCC Staging System for Stage IV Melanoma

  • Heather B. Neuman
  • Ami Patel
  • Nicole Ishill
  • Christine Hanlon
  • Mary Sue Brady
  • Allan C. Halpern
  • Alan Houghton
  • Daniel G. CoitEmail author



Survival of patients with stage IV melanoma is poor. In the current American Joint Committee on Cancer (AJCC) staging system, site of distant disease and lactate dehydrogenase (LDH) are the only prognostic factors included for stage IV disease. We sought to validate the current AJCC staging system in a contemporary, prospectively collected cohort of patients and explore additional factors that may influence prognosis.


Our prospective database was searched to identify patients with stage IV melanoma; only patients seen at our institution before developing stage IV disease were included (n = 589). Demographic, clinical, and tumor characteristics were abstracted. Univariate and multivariate assessment of prognostic factors associated with survival were performed by Cox regression.


Overall median survival was 9 months. Differential survival by AJCC substage was observed (P < .001). For each site of disease described within the AJCC staging system, an abnormal LDH level was associated with a poorer prognosis. By multivariate analysis, older age at diagnosis (as a continuous variable, hazard ratio [HR] 1.02, 95% confidence interval [95% CI]) 1.01–1.02), an abnormal LDH (HR 1.42, 95% CI 1.11–1.82), site of disease (lung HR 1.22, 95% CI .89–1.66; other viscera 1.61, 95% CI 1.18–2.21), more than one organ involvement (HR 1.27, 95% CI 1.01–1.60), and more than one metastasis (HR 2.27, 95% CI 1.65–3.14) were independently associated with poorer survival. Sex, antecedent stage, and disease-free interval were not statistically significant.


In our patient cohort, the AJCC staging system was valid. The strongest predictor of survival—the number of metastases present at the diagnosis of stage IV disease—represents a variable to consider in future staging systems.


Staging Stage IV melanoma Metastases Survival 



Supported in part by grant 5 T32 HS000066 from the Agency for Healthcare Research and Quality.


  1. 1.
    Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635–48PubMedGoogle Scholar
  2. 2.
    Unger JM, Flaherty LE, Liu PY, et al. Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials. Cancer 2001; 91:1148–55PubMedCrossRefGoogle Scholar
  3. 3.
    Keilholz U, Martus P, Punt CJ, et al. Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin. Eur J Cancer 2002; 38:1501–11PubMedCrossRefGoogle Scholar
  4. 4.
    Manola J, Atkins M, Ibrahim J, et al. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 2000; 18:3782–93PubMedGoogle Scholar
  5. 5.
    Keilholz U, Conradt C, Legha SS, et al. Results of interleukin-2–based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 1998; 16:2921–9PubMedGoogle Scholar
  6. 6.
    Falkson CI, Falkson HC Prognostic factors in metastatic malignant melanoma. An analysis of 236 patients treated on clinical research studies at the Department of Medical Oncology, University of Pretoria, South Africa from 1972–1992. Oncology 1998; 55:59–64PubMedCrossRefGoogle Scholar
  7. 7.
    Eton O, Legha SS, Moon TE, et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 1998; 16:1103–11PubMedGoogle Scholar
  8. 8.
    Brand CU, Ellwanger U, Stroebel W, et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer 1997; 79:2345–53PubMedCrossRefGoogle Scholar
  9. 9.
    Barth A, Wanek LA, Morton DL Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995; 181:193–201PubMedGoogle Scholar
  10. 10.
    Sirott MN, Bajorin DF, Wong GY, et al. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 1993; 72:3091–8PubMedCrossRefGoogle Scholar
  11. 11.
    Ryan L, Kramar A, Borden E Prognostic factors in metastatic melanoma. Cancer 1993; 71:2995–3005PubMedCrossRefGoogle Scholar
  12. 12.
    Balch CM, Soong SJ, Murad TM, et al. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1983; 1:126–34PubMedGoogle Scholar
  13. 13.
    Feun LG, Gutterman J, Burgess MA, et al. The natural history of resectable metastatic melanoma (stage IVA melanoma). Cancer 1982; 50:1656–63PubMedCrossRefGoogle Scholar
  14. 14.
    Presant CA, Bartolucci AA Prognostic factors in metastatic malignant melanoma: the Southeastern Cancer Study Group experience. Cancer 1982; 49:2192–6PubMedCrossRefGoogle Scholar
  15. 15.
    Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19:3622–34PubMedGoogle Scholar
  16. 16.
    Essner R, Lee JH, Wanek LA, et al. Contemporary surgical treatment of advanced-stage melanoma. Arch Surg 2004; 139:961–6, discussion 966-7PubMedCrossRefGoogle Scholar
  17. 17.
    Karakousis CP, Velez A, Driscoll DL, et al. Metastasectomy in malignant melanoma. Surgery 1994; 115:295–302PubMedGoogle Scholar
  18. 18.
    Petersen RP, Hanish SI, Haney JC, et al. Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. J Thorac Cardiovasc Surg 2007; 133:104–10PubMedCrossRefGoogle Scholar
  19. 19.
    Neuman HB, Patel A, Hanlon C, et al. Stage IV melanoma and pulmonary metastases: factors predictive of survival. Ann Surg Oncol 2007; 14:2847–53PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2008

Authors and Affiliations

  • Heather B. Neuman
    • 1
  • Ami Patel
    • 1
  • Nicole Ishill
    • 2
  • Christine Hanlon
    • 1
  • Mary Sue Brady
    • 1
  • Allan C. Halpern
    • 3
  • Alan Houghton
    • 3
  • Daniel G. Coit
    • 1
    Email author
  1. 1.Gastric and Mixed Tumor Service, Department of SurgeryMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Department of Epidemiology-BiostatisticsMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  3. 3.Department MedicineMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations